Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial Complex I Modulator Restores Network Resilience in Advanced Alzheimer's Disease Through Metabolic Reprogramming.

bioRxiv : the preprint server for biology·2026
Same author

Mitochondrial bioenergetic signatures differentiate asymptomatic from symptomatic Alzheimer's disease.

Communications biology·2026
Same author

Prevention of microglial activation and postoperative cognitive deficits by positive allosteric modulation of α5-GABA<sub>A</sub> receptors.

British journal of pharmacology·2026
Same author

Discovery and Preclinical Validation of a Clinically Optimized Mitochondrial Complex I Modulator for Alzheimer's Disease.

bioRxiv : the preprint server for biology·2026
Same author

The role of GABA<sub>A</sub> receptors in hippocampus-dependent cognitive functions.

Neuroscience and biobehavioral reviews·2026
Same author

Multilevel impairment of mitochondrial respiration with sex-specific signatures in inclusion body myositis.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 5, 2026

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

A Small-Molecule Mitochondrial Complex I Modulator Improves Behavioral and Mitochondrial Dysfunction in

Maltesh Kambali, Sergey Trushin, Muxiao Wang

    Biorxiv : the Preprint Server for Biology
    |June 4, 2026
    PubMed
    Summary

    Weak inhibition of mitochondrial complex I (mtCI) improves mitochondrial function and reverses behavioral deficits in a mouse model of schizophrenia. This suggests targeting mitochondrial dysfunction may offer a novel therapeutic strategy for schizophrenia treatment.

    More Related Videos

    Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
    08:15

    Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

    Published on: August 15, 2025

    Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
    06:07

    Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

    Published on: June 23, 2023

    Related Experiment Videos

    Last Updated: Jun 5, 2026

    Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
    11:47

    Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

    Published on: January 22, 2017

    Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
    08:15

    Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

    Published on: August 15, 2025

    Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
    06:07

    Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model

    Published on: June 23, 2023

    Area of Science:

    • Neuroscience
    • Mitochondrial Biology
    • Pharmacology

    Background:

    • Mitochondrial dysfunction is implicated in schizophrenia pathophysiology.
    • Weak inhibition of mitochondrial complex I (mtCI) shows neuroprotective effects in other neurodegenerative models.
    • The therapeutic potential of mtCI inhibition in schizophrenia remains unexplored.

    Purpose of the Study:

    • To investigate if weak mtCI inhibition can ameliorate mitochondrial and behavioral deficits in a mouse model of schizophrenia.
    • To explore the underlying molecular mechanisms, focusing on mitochondrial biogenesis regulators.

    Main Methods:

    • Utilized a mouse model with four copies of the Gldc gene, a model for schizophrenia.
    • Administered CP2, a weak mtCI inhibitor, for 8 weeks.
    • Assessed behavioral phenotypes using Y-maze, startle habituation, and social interaction tests.
    • Analyzed protein expression of PGC-1α and VDAC1 via Western blotting.

    Main Results:

    • CP2 treatment reversed deficits in spontaneous alternation, startle habituation, and social novelty.
    • CP2 administration normalized reduced expression of PGC-1α, a key regulator of mitochondrial biogenesis.
    • CP2 treatment also reversed reduced VDAC1 expression, crucial for mitochondrial-cytosolic metabolite exchange.

    Conclusions:

    • Weak inhibition of mtCI with CP2 effectively reverses behavioral and molecular deficits in a mouse model of schizophrenia.
    • Targeting mitochondrial dysfunction by enhancing mitochondrial biogenesis and function presents a promising therapeutic avenue for schizophrenia.